Abstract
Starting with the enhanced permeability and retention (EPR) effect discovery, nanomedicine has gained a crucial role in cancer treatment. The advances in the field have led to the approval of nanodrugs with improved safety profile and still inspire the ongoing investigations. However, several restrictions, such as high manufacturing costs, technical challenges, and effectiveness below expectations, raised skeptical opinions within the scientific community about the clinical relevance of nanomedicine. In this review, we aim to give an overall vision of the current hurdles encountered by nanotherapeutics along with their design, development, and translation, and we offer a prospective view on possible strategies to overcome such limitations.
Funder
Associazione Italiana per la Ricerca sul Cancro
Regione Lombardia
Reference152 articles.
1. There’s Plenty of Room at the Bottom;Feynman;Eng. Sci.,1960
2. Medical Nanotechnology and Nanomedicine;Tibbals,2011
3. The big picture on nanomedicine: the state of investigational and approved nanomedicine products
4. A new concept for macromolecular therapeutics in cancer chemotherapy: Mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs;Matsumura;Cancer Res.,1986
5. Vascular permeability in a human tumor xenograft: Molecular size dependence and cutoff size;Yuan;Cancer Res.,1995
Cited by
135 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献